RxBio Overview
- Year Founded
-
2007

- Status
-
Private
- Employees
-
8

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$252K
- Investors
-
2
RxBio General Information
Description
Developer of novel drugs designed for use in the mitigation of acute radiation syndrome (ARS). The company specializes in developing drugs to mitigate gastrointestinal acute radiation syndrome and also protect against lethal whole-body gastrointestinal tract, damage to the gastrointestinal tract due to radiation, chemotherapy, and various toxins, enabling the medical community and patients to combat chronic conditions effectively.
Contact Information
Website
www.rxbio.comCorporate Office
- PO Box 5389
- Johnson City, TN 37602-5389
- United States
Corporate Office
- PO Box 5389
- Johnson City, TN 37602-5389
- United States
RxBio Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
8. Grant | 18-Sep-2020 | $252K | Completed | Generating Revenue | ||
7. Later Stage VC | 21-Jul-2017 | Completed | Generating Revenue | |||
6. Grant | 01-Jan-2015 | Completed | Generating Revenue | |||
5. Grant | 01-Jan-2013 | Completed | Generating Revenue | |||
4. Grant | 01-Jan-2011 | Completed | Generating Revenue | |||
3. Seed Round | 29-Sep-2010 | Completed | Generating Revenue | |||
2. Grant | 01-Jan-2008 | $197K | Completed | Generating Revenue | ||
1. Grant | 01-Jan-2007 | $97.2K | Completed | Generating Revenue |
RxBio Patents
RxBio Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-2935677-C | Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate | Active | 30-Dec-2013 | ||
CA-2935677-A1 | Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate | Active | 30-Dec-2013 | ||
US-9567288-B2 | Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate | Active | 30-Dec-2013 | ||
US-20170226139-A1 | Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate | Inactive | 30-Dec-2013 | ||
US-20150183726-A1 | Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate | Active | 30-Dec-2013 | C07C229/26 |
RxBio Signals
RxBio Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
National Institute Of Allergy and Infectious Diseases | Government | |||
U.S. Department of Health and Human Services | Government |
RxBio FAQs
-
When was RxBio founded?
RxBio was founded in 2007.
-
Where is RxBio headquartered?
RxBio is headquartered in Johnson City, TN.
-
What is the size of RxBio?
RxBio has 8 total employees.
-
What industry is RxBio in?
RxBio’s primary industry is Drug Discovery.
-
Is RxBio a private or public company?
RxBio is a Private company.
-
What is RxBio’s current revenue?
The current revenue for RxBio is
. -
How much funding has RxBio raised over time?
RxBio has raised $2.24M.
-
Who are RxBio’s investors?
National Institute Of Allergy and Infectious Diseases and U.S. Department of Health and Human Services have invested in RxBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »